Germany · Delayed Price · Currency is EUR Fate Therapeutics Company Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors.
Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 181 |
| CEO | Bahram Valamehr |
Contact Details
Address: 12278 Scripps Summit Drive San Diego, Delaware 92131 United States | |
| Phone | 858 875 1800 |
| Website | fatetherapeutics.com |
Stock Details
| Ticker Symbol | F6T |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bahram Valamehr | Chief Executive Officer |
| Kamal Adawi | Chief Financial Officer |
| Jessica Francis | Chief Operating Officer |